Monoclonal Mouse anti‑Human PLAU / Urokinase / uPA Antibody (clone 2G6.2, N‑Terminus, WB) LS‑C40103
Monoclonal Mouse anti‑Human PLAU / Urokinase / uPA Antibody (clone 2G6.2, N‑Terminus, WB) LS‑C40103
Antibody:
PLAU / Urokinase / uPA Mouse anti-Human Monoclonal (N-Terminus) (2G6.2) Antibody
Format:
Unconjugated, Unmodified
Overview
Antibody:
PLAU / Urokinase / uPA Mouse anti-Human Monoclonal (N-Terminus) (2G6.2) Antibody
Format:
Unconjugated, Unmodified
Specifications
Description
UPA antibody LS-C40103 is an unconjugated mouse monoclonal antibody to human uPA (PLAU / Urokinase) (N-Terminus). Validated for ELISA and WB.
Target
Human PLAU / Urokinase / uPA
Synonyms
PLAU | BDPLT5 | U-PA | U-plasminogen activator | URK | Urokinase | Plasminogen activator, urinary | QPD | UPA
Reactivity
Human
(tested or 100% immunogen sequence identity)
Clonality
IgG1
Monoclonal
Conjugations
Unconjugated.
Also available conjugated with
APC,
Biotin,
FITC,
HRP,
PE.
Immunogen
Amino Terminal Fragment of uPA
Specificity
Recognizes human uPA.
Applications
- Western blot (1:1000 - 1:3000)
- ELISA
Usage
Suitable for use in Western Blot and ELISA. Western Blot: 1:1000-1:3000.
Presentation
PBS, pH 7.2, 0.1% Sodium Azide
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This antibody carries the LSBio 100% Guarantee.
LSBio Guarantee
About PLAU / Urokinase / uPA
Featured Products
Species:
Mouse, Rat
Applications:
IHC, IHC - Frozen, Western blot, ELISA
Species:
Human
Applications:
IHC, IHC - Paraffin, IHC - Frozen, Western blot, ELISA, Radioimmunoassay
Species:
Human
Applications:
Western blot, ELISA
Species:
Mouse, Rat
Applications:
IHC, IHC - Paraffin, IHC - Frozen, Western blot, ELISA
Species:
Human
Applications:
Western blot, ELISA
Species:
Rat
Applications:
IHC, IHC - Paraffin, IHC - Frozen, Western blot, ELISA
Request SDS/MSDS
To request an SDS/MSDS form for this product, please contact our Technical Support department at:
Technical.Support@LSBio.com
Requested From: United States
Date Requested: 4/26/2024